CLINICAL TRIAL SUMMARY

MDACC Study No:ID02-115 (clinicaltrials.gov NCT No: NCT00085384)
Title:A Phase I/II Study to Evaluate the Optimum Dose of Pegylated-Interferon (PEG INTRON) in Patients with Platinum Resistant Ovarian, Peritoneal or Fallopian Tube Cancer
Principal Investigator:Judith Wolf
Treatment Agent:
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the optimum biologic dose
(OBD) of PEG Intron that can be given as a treatment for patients with ovarian,
peritoneal, or fallopian tube cancer. Researchers hope to find out if PEG
Intron will help shrink or slow the growth of tumors in patients who are
considered resistant to platinum drugs. The safety of this drug will also be
studied

Hide details for General InformationGeneral Information

Disease Group:
Phase of Study:Phase I/Phase II
Treatment Agents:
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Q28 days
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Judith Wolf
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-792-7310
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults